PHILADELPHIA / SAN FRANCISCO — In a whirlwind week that spanned the American continent, leadership from METAvivor, a leading non-profit dedicated to funding research for Stage IV metastatic breast cancer (MBC), joined forces with pharmaceutical giants and patient advocacy groups to reshape the landscape of oncology care. Led by Dr. Kelly Shanahan, President of METAvivor, the series of high-level exchanges in San Francisco and Philadelphia highlighted a pivotal shift in the breast cancer community: a transition from general awareness to a laser-focus on terminal research and long-term survivorship.
The week’s events underscored the dual reality of modern MBC advocacy—a grueling schedule of policy and scientific exchange balanced by the profound emotional weight of a community fighting for its life. From the boardrooms of Genentech to the emotional corridors of the 20th Living Beyond Breast Cancer (LBBC) conference, the message was clear: patients are no longer just subjects of study; they are the primary drivers of the research agenda.
Main Facts: A Week of Strategic Engagement and Recognition
The advocacy tour commenced in San Francisco, where Dr. Shanahan represented METAvivor at Genentech’s "Insight Exchange" and "Experience Exchange." These forums served as a nexus for over 125 organizations, representing a vast spectrum of pathologies. The primary objective was to foster cross-disease collaboration and provide pharmaceutical developers with direct patient insights into the oncology pipeline.
Following the West Coast briefings, the focus shifted to Philadelphia for the 20th anniversary of the Living Beyond Breast Cancer (LBBC) MBC conference. This event is widely regarded as the premier gathering for the metastatic community, focusing on the specific needs of those living with Stage IV disease.
Key highlights from the week included:
- Changemaker Honors: Dr. Kelly Shanahan and fellow METAvivor board member Janice Cowden were formally recognized by LBBC as "Changemakers," a title reserved for individuals who have significantly altered the trajectory of MBC advocacy and support.
- Scientific and Emotional Integration: Dr. Shanahan, a retired OB/GYN, bridged the gap between clinical evidence and the psychological toll of terminal illness during a panel entitled "The emotional impact of living long-term with MBC."
- Organizational Expansion: METAvivor leadership utilized the gatherings to recruit new volunteers for critical roles, including grant reviewers and peer-to-peer support leaders.
- Clinical Breakthroughs: In a personal addendum to the organizational news, Dr. Shanahan reported significant success in her own clinical trial, with scans showing a marked decrease in the activity of her metastases after only two months of treatment.
Chronology: From Corporate Insights to Community Connection
Phase I: The San Francisco Exchanges
The week began with a deep dive into the infrastructure of pharmaceutical development. At Genentech’s "Insight Exchange," the focus was narrowed to oncology. Dr. Shanahan engaged with industry scientists to discuss the current hurdles in drug delivery and the necessity of patient-centric trial designs.
This was followed by the "Experience Exchange," a massive collaborative effort involving representatives from more than 125 organizations. This broader forum allowed METAvivor to compare notes with advocates for rare diseases and other chronic conditions, identifying commonalities in the "A to Z" of human illness. The goal of these sessions was to ensure that the patient voice is integrated into the earliest stages of drug development, rather than being an afterthought in the marketing phase.
Phase II: The Philadelphia LBBC Conference
Transitioning from the corporate environment of San Francisco to the community-driven atmosphere of Philadelphia, the METAvivor team arrived at the 20th LBBC MBC conference. This event served as a homecoming for the metastatic community.
For the METAvivor board, which typically operates via digital platforms like Zoom, the conference provided a rare opportunity for in-person synergy. Eight board members from across the United States—spanning California, New Jersey, Massachusetts, and Florida—convened to strategize and connect with the patient population they serve. Executive Director Crystal Moore and board members AJ, Alpha, Barbara, Jamil, Janice, Lynda, and Sarah were present, while Tim Bigelow maintained the organization’s presence at the exhibition booth, facilitating recruitment and public education.
Phase III: The Personal and Professional Intersection
During the conference, the narrative shifted from the organizational to the personal. Dr. Shanahan’s participation in the emotional impact panel marked a departure from her usual "science-first" approach. By discussing the loss of her career as an OB/GYN and the coping mechanisms found through advocacy, she provided a roadmap for other patients struggling with the identity crisis that often accompanies a terminal diagnosis.
Supporting Data: The Current State of MBC Research
The urgency of METAvivor’s mission is supported by sobering statistics regarding breast cancer funding and outcomes. While October is traditionally dominated by "Pink Ribbon" awareness campaigns, METAvivor points to a critical disparity in how research dollars are allocated.
The Funding Gap
According to data often cited by METAvivor, while nearly $1 billion is raised annually for breast cancer in the U.S. alone, it is estimated that only 2–5% of those funds are dedicated specifically to researching metastatic disease. Metastatic breast cancer occurs when the cancer spreads to vital organs (lungs, liver, bones, brain), and it remains the cause of nearly all breast cancer deaths—approximately 44,000 annually in the United States.
The Role of METAvivor
Since its inception, METAvivor has remained the only organization in the U.S. that dedicates 100% of its net proceeds to MBC research grants. The organization’s growth is reflected in its recruitment efforts in Philadelphia:
- Grant Reviewers: METAvivor utilizes a unique peer-review process where patients and scientists collaborate to select the most promising research projects.
- Peer-to-Peer Leadership: With the rise of "long-termers" (patients living years with MBC), the demand for specialized support groups has surged. The training of peer leaders is essential to address the unique psychological needs of Stage IV patients, which differ significantly from those in early-stage recovery.
Clinical Trial Efficacy
Dr. Shanahan’s update regarding her own clinical trial serves as a data point for the "new era" of MBC treatment. The fact that her metastases showed decreased activity within 60 days highlights the potential of targeted therapies and the importance of patient participation in trials. Currently, only about 3–5% of adult cancer patients enroll in clinical trials, a statistic advocates are desperate to increase.
Official Responses: Leadership and Vision
The presence of the METAvivor board in Philadelphia was more than a symbolic gesture; it was a strategic mobilization. Executive Director Crystal Moore emphasized the importance of the "human element" in advocacy.
"Seeing each other as ‘tiny squares on Zoom’ is our daily reality, but the energy of being in the same room—sharing hugs and remembering those we’ve lost—is what fuels this movement," Moore noted. "The recruitment of new volunteers in Philadelphia, from grant reviewers to support group leaders, ensures that our infrastructure can keep pace with our growth."
Janice Cowden, fellow board member and LBBC Changemaker, echoed this sentiment. Her recognition, alongside Dr. Shanahan, highlights a specific type of leadership within the community: the "patient-expert." These are individuals who have mastered the complexities of oncology to the point of being able to influence national policy and research directions.
The response from the broader community at the LBBC conference was one of profound engagement. The METAvivor booth served as a hub for patients looking to turn their "terminal" diagnosis into a "take action" mandate.
Implications: The Future of Metastatic Advocacy
The events of this past month signal a maturing of the MBC movement. The implications for the future of oncology are three-fold:
1. The Rise of the "Patient-Scientist"
Dr. Shanahan’s dual identity as a physician and a patient represents the future of medical advocacy. Her ability to navigate high-level exchanges at Genentech while speaking vulnerably about emotional loss at LBBC suggests that the most effective advocates of the future will be those who can speak both the language of the clinic and the language of the heart.
2. Shift in Research Priorities
The success of Dr. Shanahan’s clinical trial is a testament to the "Research, Not Just Awareness" mantra of METAvivor. As more patients survive longer with metastatic disease, the focus of research is shifting from "prevention" to "management and cure" of Stage IV. The implications for drug development are massive, as pharmaceutical companies increasingly look to the metastatic population for insights into resistance and long-term efficacy.
3. Institutionalizing Support
The training of peer-to-peer leaders suggests a move toward institutionalizing support systems that are independent of traditional hospital settings. By empowering patients to lead their own support groups, METAvivor is creating a sustainable, national network of care that addresses the isolation often felt by those with Stage IV disease.
As Dr. Shanahan concluded in her address to the community, the work is "exhausting but energizing." The progress made in San Francisco and Philadelphia serves as a reminder that while the path to a cure for metastatic breast cancer is long, the community is no longer walking it in silence. With clinical trials showing promise and a board of directors more unified than ever, the transition of MBC from a death sentence to a manageable chronic condition appears increasingly within reach.
For those interested in contributing to the mission or seeking support, METAvivor encourages visiting their Take Action page to learn about volunteer opportunities and peer-led initiatives.
About the Author
